ArticleFrontiers in pharmacology2026

Cost-effectiveness of tarlatamab versus chemotherapy for patients with small-cell lung cancer after platinum-based chemotherapy in the United States and China.

Xiaoju Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.